Insider Cluster (2 insiders) ·Filed Aug 12, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $960K total
Actionable Insight • Neutral

These director sales are routine post-vesting diversification and carry no informational signal. The strong Q2 earnings beat and raised fundamentals remain the dominant narrative. Monitor for any C-suite insider activity or changes in the 10b5-1 trading plan schedule, but no action is warranted from this cluster.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
REGN ▼ -0.59% at T+20d
NEUTRAL call ✗ call lost -0.59% · α vs SPY +1.30% · entry $797.99 → $793.26
Next anchor: T+60d in 5w
Latest observation: T+33 -9.21% FF3 residual α
Entry anchored
Aug 11, 05:22 PM ET
via 1-min bar
T+1d
+1.00%
call +1.00% · α +0.30%
$805.97
settled 7w ago
T+5d
+5.37%
call +5.37% · α +5.81%
$840.84
settled 6w ago
T+20d
-0.59%
call -0.59% · α +1.30%
$793.26
settled 23d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Two Regeneron directors sold a combined $960K in open-market sales on August 10, 2026, following the exercise of stock options. The sales are small relative to the $82.1B market cap (0.001%) and are typical post-vesting diversification by non-executive directors. The cluster occurred 14 days after a strong Q2 earnings beat (revenue +17% YoY, EPS 40% above consensus), suggesting routine portfolio management rather than a bearish signal. The historical calibration shows strong positive T+20 alpha on prior REGN reports (avg +9.66%), but this cluster's trivial size and director-only composition do not warrant a directional call.

Key Financial Metrics

Direction
selling
Total Value
$960.0K
Insiders
2

Key Facts

  • Two directors sold a total of 1,200 shares for $960K on August 10, 2026
  • Sales were open-market transactions following option exercises (non-cash exercises of $0 and $287K/$301K)
  • Total sales represent ~0.001% of REGN's $82.1B market cap — well below the 0.1% materiality threshold
  • Cluster occurred 14 days after Q2 2026 earnings beat (revenue $4.29B, +17% YoY; non-GAAP EPS $14.29 vs consensus $10.20)
  • No C-suite executives participated; only two independent directors

Financial Impact

Insider sales of $960K represent 0.001% of market cap — trivial and non-material

Risk Factors

  • No material risk identified from this cluster; the trivial size and director-only composition make it non-informative

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (37 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-REGN-1786612390669
26 reports for REGN
Performance horizon
85% Hit rate 11 of 13 directional calls best @ T+60▲ +26.47%May 21, 2026
Filters
Rows
Reports for REGN — sortable, filterable
TypeNow
Oct 1, 2026
1d ago
ANALYST-UPGRADE
BULLISH ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$843.47 $781.49▼ −7.35%▼ −6.20%$735.20 (−12.84%)
Aug 24, 2026
5w ago
Court Ruling
BULLISH ★ 5/10
$828.50 $799.08▼ −3.55%▼ −4.02%$735.20 (−11.26%)
Aug 20, 2026
6w ago
Press Release
NEUTRAL ★ 5/10
$826.64 $807.71▼ −2.29%▼ −3.40%$735.20 (−11.06%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$797.99 $840.84▲ +5.37%▲ +5.81%$735.20 (−7.87%)
Aug 11, 2026
7w ago
Court Ruling
BULLISH ★ 5/10
$797.00 $807.57▲ +1.33%▲ +1.73%$735.20 (−7.75%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 7/10
$738.34 $772.11▲ +4.57%▲ +0.95%$735.20 (−0.43%)
Jul 30, 2026
9w ago
Press Release
BULLISH ★ 7/10
$738.34 $772.11▲ +4.57%▲ +0.95%$735.20 (−0.43%)
Jul 27, 2026
9w ago
Press Release
BEARISH ★ 6/10
$695.18 $759.24▼ −9.21%▼ −6.95%$735.20 (−5.76%)
Jul 17, 2026
11w ago
Press Release
NEUTRAL ★ 3/10
$676.69 $651.91▼ −3.66%▼ −2.97%$735.20 (+8.65%)
Showing 10 of 26

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 13, 2026